<DOC>
	<DOCNO>NCT00217464</DOCNO>
	<brief_summary>RATIONALE : Estrogen may cause growth prostate cancer cell . Hormone therapy use fulvestrant may fight prostate cancer block use estrogen tumor cell . PURPOSE : This phase II trial study well fulvestrant work treat patient recurrent prostate cancer .</brief_summary>
	<brief_title>Fulvestrant Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether fulvestrant slow rise prostrate-specific antigen ( PSA ) level patient early recurrent adenocarcinoma prostate radical prostatectomy irradiation . Secondary - Determine utility monitoring serum PSA patient treat drug . - Determine safety drug patient . - Determine change bone mineral density marker bone resorption patient PSA-only failure treat drug . OUTLINE : This open-label , single group assignment study . Patients receive fulvestrant intramuscularly day 0 , 14 , 28 . Treatment repeat month absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 32 patient accrue study 84 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Early recurrent disease , define 1 follow criterion : Prostatespecific antigen ( PSA ) ≥ 2.0 ng/mL AND clearly rise within past 3 month patient underwent prior prostatectomy without radiotherapy PSA ≥ 4.0 ng/mL AND clearly rise low value obtain within past 6 month patient underwent prior definitive radiotherapy No evidence clinical recurrence , * define follow criterion : Digital rectal exam negative No local recurrence CT scan MRI pelvis No evidence bone metastasis bone scan NOTE : *Prostascint scan result consider evidence recurrence Underwent prior curative treatment comprise radical prostatectomy without adjuvant radiotherapy OR definitive radiotherapy alone Testosterone ( total free ) &gt; low limit normal PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC &gt; 3,500/mm^3 Platelet count &gt; 100,000/mm^3 No history bleed diathesis Hepatic INR &lt; 1.6 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN No severe hepatic impairment would preclude study participation compliance Renal Creatinine ≤ 2.0 mg/dL No severe renal impairment would preclude study participation compliance Cardiovascular No unstable uncompensated cardiac condition would preclude study participation compliance Pulmonary No unstable uncompensated respiratory condition would preclude study participation compliance Other No history hypersensitivity active inactive excipients fulvestrant ( e.g. , castor oil ) No severe condition would preclude study compliance ( e.g. , abuse alcohol drug psychotic state ) participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 6 month since prior neoadjuvant adjuvant androgen deprivation therapy luteinizing hormonereleasing hormone antagonist therapy No prior concurrent hormonal therapy Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery See Disease Characteristics Other More 4 week since prior experimental drug treatment No concurrent anticoagulant therapy except antiplatelet therapy No concurrent therapy prostate cancer No concurrent therapy know suspect alter androgen metabolism androgen level</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>